Investigational Drug Details
| Drug ID: | D470 |
| Drug Name: | Nandrolone decanoate |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB08804 |
| DrugBank Description: | C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of estradiol to resemble testosterone but less one carbon at the 19 position. It is a schedule III drug in the U.S. |
| PubChem ID: | 9677 |
| CasNo: | 360-70-3 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C |
| Structure: |
|
| InChiKey: | JKWKMORAXJQQSR-MOPIKTETSA-N |
| Molecular Weight: | 428.6472 |
| DrugBank Targets: | Androgen receptor; Proto-oncogene c-Fos; 5-hydroxytryptamine 2 receptor; 5-hydroxytryptamine receptor 1B; Insulin-like growth factor 1 receptor; Dopamine receptor |
| DrugBank MoA: | Nandrolone is an androgen receptor agonist. The drug bound to the receptor complexes which allows it to enter the nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects. |
| DrugBank Pharmacology: | Nandrolone is an anabolic steroid occurring naturally in the human body, albeit in small quantities. Nandrolone increases production and urinary excretion of erythropoietin. It may also have a direct action on bone marrow. Nandrolone binds to the androgen receptor to a greater degree than testosterone, but due to its inability to act on the muscle in ways unmediated by the receptor, has less overall effect on muscle growth. |
| DrugBank Indication: | For the treatment of refractory deficient red cell production anemias, breast carcinoma, hereditary angioedema, antithrombin III deficiency, fibrinogen excess, growth failure and Turner's syndrome. It is also indicated in the prophylaxis of hereditary angioedema. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L3539 | NCT00494767 | PHASE1 | COMPLETED | NO | 2006-09-29 | 2017-08-07 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|